At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
Administration of Lotemaxdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Ocular Surface Inflammatory Mediators and Ocular Surface Metrology Effected by Lotemax
In Brief
A clinical study evaluating Administration of Lotemax for Sjogren's Disease. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effects of an anti-inflammatory drug (Lotemax®) on the surface of the eye and tear film (a film that coats the eye which is made up of oil and water).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSjogren's Disease
CountriesUnited States
CollaboratorsBausch & Lomb Incorporated
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedDec 2014
Primary CompletionAug 2015
TodayJul 2026
First PostedDec 23, 2014
Enrollment StartApr 1, 2014
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.5 years ago
Interventions
Administration of Lotemaxdrug
An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.